SCHEMBL5762437

SCHEMBL5762437

CCOC(=O)C(Cc1ccc(O)c2c1CCCC2)OCC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NLRP3 Q96P20 2/20 0.35
PPARA Q07869 4/20 0.34
MAPT P10636 4/20 0.33
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA7 P43166 3/20 0.33
CA9 Q16790 3/20 0.33
CA14 Q9ULX7 3/20 0.33
KDM4E B2RXH2 3/20 0.33
PPARG P37231 1/20 0.33
TDP1 Q9NUW8 2/20 0.33
HPGD P15428 2/20 0.33
MAPK1 P28482 2/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373090 0.91 NLRP3 (0.36) KMT2AMEN1NPC1RAB9ANLRP3
SCHEMBL6451333 0.88 PPARA (0.46) PPARAPPARG
SCHEMBL3374372 0.80 MAOA (0.34) NPC1RAB9APPARACA12CA1
SCHEMBL3370775 0.76 NR3C1 (0.43) KMT2AMEN1NPC1PPARAMAPT
SCHEMBL3370060 0.75 ESR1 (0.43) NLRP3PPARACA12CA1CA2
SCHEMBL5024469 0.75 ESR1 (0.43) NLRP3PPARACA12CA1CA2
SCHEMBL978301 0.75 ESR1 (0.46) PPARACA12CA1CA2CA7
SCHEMBL6718321 0.75 CA12 (0.45) KMT2AMEN1NPC1PPARACA12
SCHEMBL2434050 0.74 ALDH1A1 (0.53) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL29024370 0.73 SMN1; SMN2 (0.45) KMT2AMEN1NPC1RAB9ANLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392295-B1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2006-05-31 EP disclosed
EP-1392295-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2004-03-03 EP disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
WO-2002092084-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG KMT2A 4142/4885MEN1 4859/4885NPC1 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.